Human proislet peptide - CureDM

Drug Profile

Human proislet peptide - CureDM

Alternative Names: HIP2B; Pancreate

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CureDM
  • Class Antihyperglycaemics; Peptide fragments
  • Mechanism of Action Cell differentiation stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(Treatment-experienced) in USA (SC, Injection)
  • 15 Dec 2016 Biomarkers information updated
  • 19 Sep 2016 CureDM completes a phase I clinical trial in Type-2 diabetes mellitus (Treatment-experienced) in USA (SC) (NCT01933256)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top